Copy Link Print Information

Lorigerlimab

(Synonyms: MGD019)
Customer Review

Based on 1 Customer Validation

Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART). Lorigerlimab can block PD-1 and CTLA-4, and improves T-cell responses. Lorigerlimab can be used for research of metastatic castration-resistant prostate cancer (mCRPC).

For research use only. We do not sell to patients.

  • Purity: 97.5%
  • CAS No.: 2416595-46-3
  • Molecular Weight:166.4 kDa
  • Storage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Experimental Validation Results for Lorigerlimab
  • Experimental Validation Results for Lorigerlimab
  • Experimental Validation Results for Lorigerlimab
  • Experimental Validation Results for Lorigerlimab
  • Lorigerlimab Chemical Structure
    Lorigerlimab Chemical Structure
CAS No.: 2416595-46-3
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Lorigerlimab Product Recommendations:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products
Keywords
100 mg

Get Quote In-stock

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • 1/16

    [V-kappa'-VH-h-CH2-CH3_V-kappa-VH']2

  • 1/16

    Immobilized PD-1 Protein, Human (143a.a, HEK293, His, HY-P7396) can bind Lorigerlimab. The EC50 for this effect is 36.2 ng/mL.

  • 1/16

    Immobilized CTLA-4 Protein, Human (HEK293, HY-P72959) can bind Lorigerlimab. The EC50 for this effect is 38.3 ng/mL.

  • 1/16

    Flow Cytometry analysis of Raji cells labelling CTLA4 (red) with Lorigerlimab (HY-P99714). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 (S228P) kappa (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

  • Lorigerlimab Chemical Structure
    1/16
  • Lorigerlimab
  • Immobilized PD-1 Protein, Human (143a.a, HEK293, His, HY-P7396) can bind Lorigerlimab. The EC50 for this effect is 36.2 ng/mL.
  • Immobilized CTLA-4 Protein, Human (HEK293, HY-P72959) can bind Lorigerlimab. The EC50 for this effect is 38.3 ng/mL.
  • Flow Cytometry analysis of Raji cells labelling CTLA4 (red) with Lorigerlimab (HY-P99714). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 (S228P) kappa (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
  • [V-kappa'-VH-h-CH2-CH3_V-kappa-VH']2